Jan 28,2023

Why Preventive Oncology is an Untapped Revenue Source for Today’s Health Systems

One area with immense potential for generating revenue is oncology, where there is a significant unfulfilled need for cancer prevention that could also drive innovation. By redirecting oncology programs towards prevention, it is possible to boost the usage of existing clinical services, free up staff for more rewarding, high-value work, and establish oncology programs as pioneers in early cancer detection and prevention.

View Analyst & Ambassador Comments
Go to original news
Jan 30,2023

NHS trials AI technology offering same-day diagnosis of aggressive lung cancer which kills 35,000 Britons each year

The software, developed by Indian tech company Qure.ai is being rolled out across Greater Manchester as part of a pilot study being led by AstraZeneca involving more than 250,000 people over the next six months. The program analyses X-ray scans immediately after they are carried out and alerts doctors if any worrying signs are spotted. Doctors reviewing x-rays for possible signs of lung cancer can take up to a week to provide a diagnosis, which can harm the patient's long-term prospects .

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 30,2023

Harnessing the power of innovative science to transform the future of healthcare

AstraZeneca has established the A.Catalyst Network, an interconnected and dynamic collective of over 20 health innovation hubs, to collaborate with diverse stakeholders such as healthtech start-ups, local governments, and cross-industry partners, in addressing present-day challenges and enhancing affordable and equitable healthcare access. One of AstraZeneca's collaborators is Qure.ai, a company that specializes in the development of deep learning algorithms for radiology image interpretation. The company's chest X-ray interpretation tool, known as "qXR," can identify and pinpoint up to 29 different abnormalities, including those that may be suggestive of lung cancer.

View Analyst & Ambassador Comments
Go to original news
Jan 31,2023

COTA, Inc. Forms Strategic Real-World Data Research Partnership with the Clinical Research Data Sharing Alliance

COTA, Inc., a company specializing in oncology real-world data and analytics, has become a member of the Clinical Research Data Sharing Alliance (CRDSA). This is a non-profit alliance that includes biopharmaceutical companies, data sharing platforms, academic institutions, and service and technology partners, working together to expedite the discovery and provision of life-saving treatments to patients by leveraging high-quality clinical trials and real-world data.

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 31,2023

Mark Cuban Cost Plus Drug Company partners with digital cancer care tool

OncoPower, a cancer care support company, has teamed up with Mark Cuban Cost Plus Drug Company (MCCPDC) to provide reduced-price prescription drugs through a new service called the Medication Savings Suite. This suite will be integrated into OncoPower's Pill Reminder Tool, which will notify patients of less expensive generic drug alternatives offered by MCCPDC when a patient enters a new medication into the tool. OncoPower offers oncology patients counseling, cancer community support groups, educational videos, access to experts and information on clinical trials.

COLLABORATION PARTNERSHIP

#product & service

#platform

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 31,2023

Qure.ai validated on Fujifilm’s AI-enabled platform REiLI®

Qure's AI-powered chest X-ray product, qXR, has been validated on Fujifilm's REiLI® platform, which features artificial intelligence capabilities. Qure and Fujifilm have a longstanding partnership and are extending their collaboration with this successful validation. In addition, qXR has been incorporated into Fujifilm's modality solutions, such as the FDR nano mobile X-ray device and FDR Xair portable X-ray devices. The product is being used in clinical settings to identify TB, COVID-19, lung cancer, and other critical symptoms in situations where there is a shortage of medical professionals.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Jan 31,2023

Jasper Health And Non-Profit Coalition Launches Jasper Community, A First-Of-Its-Kind, Peer-to-Peer Social Support Network For Those With Cancer And Survivors

Jasper Health, in partnership with several non-profit cancer support organizations, has introduced a new member community network called Jasper Community. This proprietary peer-to-peer network is now accessible to nearly 17,000 members of Jasper Health, and has been designed to promote mutual support and exchange of information by creating personalized connections. The network is especially beneficial for health plans, employers, and cancer centers seeking to develop a unique community to complement their existing social support services. The network is overseen by certified Jasper Care Coaches and leverages smart technology to enable members to select and join subgroups. These subgroups are then integrated into a personalized activity feed where members can share information, engage with each other, send direct messages, and create personal blogs.

PRODUCT

#platform

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 01,2023

Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium

Veracyte, Inc. today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 02,2023

National Employer Marketplace Selects Jasper Health As First Oncology Solution Benefit

Jasper Health is thrilled to announce being selected as the first oncology solution for the National Employer Marketplace: PlanSource. Under the partnership with PlanSource, Jasper Health’s digital platform will be offered exclusively to the employer market through the PlanSource digital marketplace. Our personalized digital oncology solution with one-on-one coaching and support is now available to over 4,000 employer groups across the US.

COLLABORATION PARTNERSHIP

#institution

#coaching

#rpm

View Analyst & Ambassador Comments
Go to original news
Feb 02,2023

Massive Bio is named to the New York City Digital Health 100

Massive Bio, a leader in the use of artificial intelligence (AI) to match cancer patients to clinical trials, is honored to announce that it has been named to the New York Digital Health 100 (DH100) for the second consecutive year. The DH100, which is published annually by Digital Health New York (DHNY), showcases the most exciting and innovative health start-ups in the New York region and is featured in the New York Healthcare Innovation Report 2023.

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY